Psychology Today | 07.07.2026 22:40
On July 1, 2026, Medicare launched the GLP-1 Bridge Program for Foundayo (orforglipron), Wegovy (semaglutide), and Zepbound (tirzepatide). For the next 18 months, the program flattens the price of these medications, which are commonly prescribed in primary care settings for weight loss, from an upward range of more than $1000 per month to just $50 per month. To be eligible, beneficiaries must have a body mass index (BMI) of at least 35, or 27-30 if they have another qualifying medical condition like diabetes or a history of heart attack or stroke. Nearly 4 million people are expected to meet criteria.
